Fig. 1From: Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinomaResearch overview and design of Mendelian randomization analysis. It should satisfy the following criteria: (1) the IVs are not related to the condounders (B1); (2) the IVs are related to the exposure factors (B2); (3) the IVs are not directly related to the outcomes (B3). IVs: instrumental variables; LUAD: lung adenocarcinamaBack to article page